Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Endocrinology > Pharm 39 - DB > Flashcards

Pharm 39 - DB Flashcards

1
Q

what is T1DM

A

i. Destruction of beta cells results in an inability to produce insulin
1) Usually autoimmune
2) Require around the clock insulin supplementation
ii. Typical, usual patient
1) Underweight, child/adolescent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is T2DM

A

i. Resistant to the effects of insulin
1) A progressive loss of insulin secretion starts to result in beta cells that do not function properly and ultimately stop producing insulin as well
2) Usually present originally with cells that do not respond to the insulin and eventually will end up with cells that do not respond to insulin and cells that cannot produce insulin
ii. Typical, usual patient
1) Overweight, adult
2) Can see metabolic syndrome, CVD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Amylin: increases _____ secretion

Pharmacologic congener: _________

A

Amylin: increases insulin secretion

Pharmacologic congener: Pramlintide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

This drug reduces appetite, decreases gastric motility/slows gastric emptying, lowers post-prandial glucose peak, and decrease glucagon release

A

amylin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

A satiety hormone - tells the body that they are full

A

amylin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  • Produced in and released by the pancreatic beta cell and is co-secreted with insulin
  • Only other FDA approved med for T1DM other than insulin
A

amylin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Glucagon - increases ______ secretion

Pharmacologic congener: ________

A

Glucagon - increases insulin secretion

Pharmacologic congener: Glucagon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

glucagon administration

A

ii. Given in subQ, IM, or IV preps

1) Used IV for hypoglycemic emergencies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Secreted by the pancreatic alpha cells to oppose insulin

A

Glucagon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

1) Causes an increase in blood glucose levels through glycogenolysis
2) Breaks down glycogen stores to glucose

A

Glucagon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

MOA: Glycogenolysis: breaks down glycogen stores of glucose

A

Glucagon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Note about Glucagon use

A
  • only effective if glycogen stores are available in that individual
  • must replenish stores after administering this medication
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Glucagon-like peptide - increases _____ secretion

Pharmacologic congener: _______

A

Glucagon-like peptide - increases insulin secretion

Pharmacologic congener: GLP-1’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Secreted by the L cells in the intestines

A

Glucagon-like peptide (GLP-1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

1) Potent stimulator of insulin synthesis and release
2) Inhibits glucagon secretion
3) Slows gastric emptying

A

Glucagon-like peptide (GLP-1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Somatostatin - decreases _____ secretion

Pharmacologic congener: ________

A

Somatostatin - decreases insulin secretion

Pharmacologic congener: Octreotide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

uses:

1) Treats acromegaly
i) Decreases GH, IGF-1
2) Metastatic, carcinoid tumors
i) Inhibits serotonin release
3) Vasoactive intestinal peptide-secreting tumor

A

Glucagon-like peptide (GLP-1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Similarities among the various insulin preparations:

A

i. All products on the market now are human forms of insulin
1) All equipotent (equal serum concentrations)
2) Given by injection (usually SubQ)
1) Only insulin-R is given IV route

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Differences among the various insulin preparations:

A

Based on their PKs, onset, and duration of action only

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Rapid-acting insulin

A
  • given with meals

- Acts quickly and wears off quickly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Short-acting insulin

A
  • not quite as quick as rapid; lasts slightly longer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Intermediate-acting insulin

A

Acts slower; lasts longer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Long-acting insulin

A

Slowest onset; longest duration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

what modifications are made to make a rapid-acting insulin faster acting than regular insulin?

A

a. Longer lasting insulin has a hexagonal shape that forms a hexamer
i. When the insulin breaks down into monomers and dimers, the body’s circulation can absorb it from the subcutaneous tissues and the insulin is then considered active

b. Insulin-R does not have a hexamer form and is not altered
i. Makes it a very active IV insulin form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

List the diabetes medication classes most likely to incite hypoglycemia (in order of risk)

A
  1. Insulin
  2. Sulfonylureas: first generation
  3. Insulin’s combined with amylin
  4. Oral agents of antihyperglycemic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Hypoglycemic reactions are most common complication of _____ therapy

A

Hypoglycemic reactions are most common complication of insulin therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Excessive insulin causes hypoglycemia in a dose-dependent fashion, esp if:

A

1) Inadequate carb consumption
2) Unusual physical exertion
3) Too larger of a dose of insulin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Drug that causes severe hypoglycemia, esp. in elderly

A

Sulfonylureas: first generation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

How do you treat a patient with a hypoglycemic episode that is conscious?

Administer what?

Monitor what?

Dosage? How does that effect the labs?

A

i. 15 grams oral glucose
1) Monitor blood glucose
1) 1 tablet: 4 grams; 4 tablets = 16 grams of glucose
i) Glucose levels will increase 16 points
2) Repeat dose if necessary after 15 minutes

30
Q

How do you treat a patient with a hypoglycemic episode that is unconscious?

Drug of choice?

If in hospital, what is used?

A

i. Glucagon is treatment of choice

ii. If in hospital, give IV glucose

31
Q

Explain the MOA of the sulfonylureas

A

a. Secretagogues that close the ATP K+ pump of the beta cells to prevent the release of K+ from the cells
1) This causes massive depolarization of the cells and over stimulation of the release of insulin
2) This allows the cell to skip over the step of increasing the ATP : ADP ratio from the increasing levels of glucose
1) Bypasses the necessary glucose to trigger insulin release
1) Results in hypoglycemia

32
Q

1) Activates the AMP-activated protein kinase to reduce hepatic resistance to insulin
1) Makes liver respond better to insulin
i) Decreased hepatic and perhaps renal, glucose production and release
2) Slows glucose absorption from GI tract to slow and evens out glucose absorption during meals

What drug has this MOA?

A

metformin

33
Q

How is metformin eliminated?

A

renally

34
Q

Contraindications to metformin?

A

1) Renal disease
1) eGFR < 45 mL/min at new onset of use of this drug
2) STOP the drug if eGFR is < 30 mL/min
2) Acute/unstable heart failure
1) Can increase risk of lactic acidosis

35
Q

ADE of metformin

A

GI complaints:

1) N/D, cramping
2) GI upset: take at end of meal
3) Titrate dose over days to weeks

May reduce B12 absorption

36
Q

i. MOA: insulin sensitizer
1) Agonist of PPAR-gamma receptor
1) Receptor is found in adipose tissue
i) Secondarily on cardiac, skeletal, and smooth muscle
Insulin sensitizers at peripheral insulin responsive tissues

A

Thiazolidinediones

37
Q

How long do you need to wait with Thiazolidinediones to see an A1C change?

A

at least one month

38
Q

Contraindications to Thiazolidinediones

A

1) Heart failure patients
2) Bladder cancer
3) Liver disease

39
Q

ADE of _____:

1) Can promote new growth of adipose tissue
2) Macular edema
3) Anemia
4) Bone mineral density loss (Increased fracture risk in women)
5) Weight gain
6) Water retention (Can worsen heart failure signs/symptoms)
7) Must monitor liver enzymes (If increases 2.5x the normal limits, must D/C this drug)

A

Thiazolidinediones

40
Q

Thiazolidinediones drugs (2)

A

“-litazone”s

Pioglitazone
Rosiglitazone

41
Q

MOA: Stops the release of K+ from the beta cell to cause depolarization of the cell and release of insulin

A

Sulfonylureas

Glinides

42
Q

Primary contraindications of sulfonylureas

A

can induce sulfa allergies

43
Q

Glyburide is ___ as likely as glipizide or glimepiride to induce ___________

A

Glyburide is 2x as likely as glipizide or glimepiride to induce hypoglycemia

44
Q

Glinides drugs (2)

A

Non-sulfonylureas/short-acting secretagogues: repaglinide, nateglinide

45
Q

Perk of glinide drugs

A
  1. Patients with sulfa allergies can take these medications
46
Q

when do are glinides taken

A

Used postprandially

47
Q

glinides require how many doses

A

Require 3 to 4 doses a day

48
Q

a less potent drug than SUs and has a shorter duration of action than SUs

A

glinides

49
Q

Can you use short acting secretagogues (like the glinides) with the long-acting secretagogues (SUs)?

A

NO - contraindicated as severely hypoglycemic and the MOAs are too similar

50
Q

MOA:

1) Stimulates insulin synthesis and release
2) Inhibits glucagon secretion
3) Slows gastric emptying
4) Produces an anorectic effect (suppresses appetite)

A

Glucagon-like-peptide (GLP)-1 agonists

51
Q

Glucagon-like-peptide (GLP)-1 agonists drugs (3)

A

“-tide”s

exenatide
exenatide ER
liragultide
dulaglutide

52
Q

Primary contraindications:

1) Possible thyroid C cell tumors
2) Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome, Type 2
3) Patient on a DPP-4 inhibitor

A

Glucagon-like-peptide (GLP)-1 agonists drugs

53
Q

ADE of GLIP-1 agonists (5)

A

1) Significant nausea
2) HA and infections
3) Anorectic effects can cause too much weight loss
4) Can slow absorption of oral drugs
5) Must watch sugars when added to insulin or secretagogues

54
Q

Severe, serious ADE of GLIP-1 agonists (4)

A

Pancreatitis, immunologic reactions, AKI, angioedema

55
Q

This drug inhibits an enzyme that enhances endogenous GLP-1 activity. This subsequently increases the cleaving of polypeptide pro-glucagon to make more GLP-1 to stimulate insulin synthesis and release.

A

Dipeptidyl peptidase (DPP)-4 inhibitors

56
Q

A specific drug class that works exceptionally well in combo with Metformin to reduce A1C up to 1.5 - 2%.

A

Dipeptidyl peptidase (DPP)-4 inhibitors

57
Q

ADE of Dipeptidyl peptidase (DPP)-4 inhibitors

A

Hypoglycemia with concurrent SU use

58
Q

SGLT-2 inhibitors reduce risk of…

A

heart failure and worsening renal dysfunction

59
Q

MOA: Increase urinary excretion of filtered glucose by inhibiting the reabsorption of glucose at a specific cell membrane channel in the proximal convoluted tubules

A

Sodium Glucose co-Transporter-2 inhibitors (SGLT-2 inhibitors)

60
Q

A DB drug that has a low risk of inducing hypoglycemia but is only able to work if the blood glucose level is > 100 or so

A

Sodium Glucose co-Transporter-2 inhibitors (SGLT-2 inhibitors)

61
Q
  • Slight weight loss effect due to osmotic release of water/sodium
  • Also helps to reduce BP this way!
A

Sodium Glucose co-Transporter-2 inhibitors (SGLT-2 inhibitors)

62
Q

Sodium Glucose co-Transporter-2 inhibitors (SGLT-2 inhibitors) contraindications

hint: remember MOA!

A

1) Renal disease (individuals less than 30mL/min eGFR)

2) Hypotensive patients

63
Q

ADE of ____ are:

1) Hyponatremia as the drug inhibits the reabsorption of glucose AND sodium
2) Increased GU infections (UTI’s and candidiasis)
3) Diabetic ketoacidosis with euglycemia
4) Increased risk of amputation, fournier gangrene, fracture risk

A

Sodium Glucose co-Transporter-2 inhibitors (SGLT-2 inhibitors)

64
Q

Best drugs to reduce A1C when treating DB: (think of two)

A
  1. Metformin

2. Metformin + GLP-1

65
Q

Best drug to use when avoiding hypoglycemia

A

SGLT-2 inhibitors

66
Q

Insulin is first choice in these situations: (5)

A

i. Hospitalized for hyperglycemia or outpatient with severe hyperglycemia
ii. Pregnancy
iii. Chronic kidney disease
iv. Heart failure
v. Contraindications to metformin or other oral agents

67
Q

A specific drug that has the following problems:

i. Drug seemed to have a higher MI and liver risk - sanction was later removed
ii. Bladder cancer possible risk - not able to discern
iii. requires liver enzyme monitoring (if see a 2.5x increase, must D/C)

A

Pioglitazone (Thiazolidinediones drug class)

68
Q

A specific drug that was associated with an increased MI risk (there’s actually two of them)

A

Pioglitazone (Thiazolidinediones drug class)

Rosiglitazone (Thiazolidinediones drug class)

69
Q

Moderate intensity statin therapy is indicated in…

A

People with DB and aged 40 - 75

70
Q

High intensity statin therapy is indicated in…

A

People with DB and:

i. Anyone with atherosclerotic CV disease
ii. Anyone with a > 7.5% 10 year CV disease risk

71
Q

List the two most commonly used antiplatelet drugs used in patients with diabetes.

A
  1. ASA (81mg)

2. Clopidogrel

Endocrinology (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions